What's Happening?
Alnylam Pharmaceuticals has presented new clinical and real-world data at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26) regarding its cardiovascular portfolio. The data supports the use of vutrisiran, a transthyretin
silencer, as a first-line treatment for patients with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The findings demonstrate improvements in health-related quality-of-life and consistent benefits across the ATTR-CM disease spectrum. Additionally, Alnylam shared pooled Phase 2 safety data for zilebesiran, an investigational RNAi therapeutic for hypertension management, which shows promise for continuous blood pressure control. The company is advancing its cardiovascular outcomes trial, ZENITH, to further evaluate zilebesiran's efficacy.
Why It's Important?
The presentation of these findings is significant as it highlights the potential of RNAi therapeutics to deliver effective and durable treatments for cardiovascular diseases. Vutrisiran's ability to improve quality-of-life and reduce disease progression in ATTR-CM patients could transform treatment approaches for this debilitating condition. Zilebesiran's potential for continuous blood pressure control offers a novel approach to managing hypertension, a major risk factor for cardiovascular disease. These developments could lead to improved patient outcomes and influence future treatment protocols in the U.S. healthcare system.
What's Next?
Alnylam plans to continue its evaluation of zilebesiran in the ZENITH trial, aiming to establish its efficacy in patients with hypertension and high cardiovascular risk. The company is also focused on expanding the use of vutrisiran across different patient subgroups with ATTR-CM. As these trials progress, Alnylam's findings could lead to new FDA approvals and broader adoption of RNAi therapeutics in cardiovascular care.
